|
Accession Number
|
PB2013-101556
|
|
Title
|
Axerion Therapeutics Generally Claimed Allowable Recovery Act Grant Costs.
|
|
Publication Date
|
Sep 2012
|
|
Media Count
|
15p
|
|
Personal Author
|
N/A
|
|
Abstract
|
Axerion Therapeutics (the grantee), established in 2009, is a private biotechnology company focused on developing therapeutics for neurological diseases and injuries. NIH awarded the grantee a Recovery Act grant of $3 million for research related to neurological recovery from spinal cord injury and stroke. The grant budget period is April 15, 2010, through March 31, 2013. As of March 31, 2011, the grantee had claimed $950,844 under the grant; we reviewed the total amount claimed by the grantee. Our objective was to determine whether costs claimed by the grantee were allowable under the terms of the grant and applicable Federal regulations.
|
|
Keywords
|
American Recovery and Reinvestment Act of 2009
Audits
Axerion Therapeutics
Cost analysis
Grants management
Inspectors general
Investigations
National government
Public Law 111-5
Recovery Act
US NIH
|
|
|
Source Agency
|
Department of Health and Human Services, Washington, DC
|
|
NTIS Subject Category
|
44B - Agency Administrative & Financial Management
44S - Legislation & Regulations
70E - Research Program Administration & Technology Transfer
70B - Management Practice
|
|
Corporate Author
|
Department of Health and Human Services, Washington, DC. Office of the Inspector General.
|
|
Document Type
|
Technical report
|
|
Title Note
|
N/A
|
|
NTIS Issue Number
|
1303
|
|
Contract Number
|
N/A
|
